GlassScriptPhysician profile
Robert L Schultze
NPI 1417933540
$148,757.52
in general payments reported to CMS, 2019-2025
38 companies · $78K in 2025
The $78K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $10K · 2021: $7,580 · 2022: $5,063 · 2023: $3,155 · 2024: $3,613 · 2025: $78K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $71K · Food and Beverage: $12K · Travel and Lodging: $1,650 · Education: $25.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $70,752.54 |
| Food and Beverage | $12,049.86 |
| Travel and Lodging | $1,649.67 |
| Education | $25.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $75,653.46 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $25,179.92 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $22,458.48 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $9,509.77 | 2019-2021 | |
| Alcon Vision LLC | $3,595.84 | 2019-2025 | Clareon, Argos, Eysuvis |
| Eyevance Pharmaceuticals LLC | $1,418.97 | 2019-2023 | Flarex |
| Bausch & Lomb Americas INC. | $1,382.90 | 2022-2025 | Miebo, Envista Mx60 Iol, Xiidra |
| Mallinckrodt Hospital Products INC. | $1,275.28 | 2020-2025 | Acthar |
| Abbvie INC. | $1,071.77 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Oyster Point Pharma, INC. | $1,020.91 | 2022-2024 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sight Sciences, INC. | $745.49 | 2021-2023 | Omni Surgical System |
| Ocular Therapeutix, INC. | $709.49 | 2019-2025 | Dextenza |
| Glaukos Corporation | $659.85 | 2022-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System, Idosetr |
| Tarsus Pharmaceuticals, INC. | $613.85 | 2024-2025 | Xdemvy |
| Beaver-Visitec International, INC. | $598.50 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $436.28 | 2020-2025 | Oxervate |
| Allergan, INC. | $428.77 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $388.48 | 2020-2023 | Tecnis Simplicity |
| Novartis Pharmaceuticals Corporation | $363.21 | 2019-2023 | |
| Galderma Laboratories, L.P. | $220.96 | 2020-2021 | |
| Rxsight INC | $219.14 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Amgen INC. | $127.45 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $122.62 | 2024 | Vevye |
| Ani Pharmaceuticals, INC. | $110.26 | 2025 | Purified Cortrophin Gel |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $96.76 | 2025 | |
| Spark Therapeutics, INC. | $91.82 | 2019 | |
| Horizon Therapeutics Plc | $40.47 | 2022-2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $38.56 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
| Astellas Pharma US INC | $32.45 | 2025 | Izervay |
| New World Medical,INC. | $28.84 | 2023 | |
| Shire North American Group INC | $22.09 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.71 | 2019 | |
| Omeros Corporation | $19.70 | 2020 | |
| Merz North America, INC. | $19.60 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $18.37 | 2022 | |
| Eyepoint US, INC. | $17.50 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schultze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.